Review article · 3 Jul 2025
Research articlePublished 13 Nov 2018
Patterns of Outcome in Human Papilloma Virus Positive Oropharyngeal Squamous Cell Carcinoma Treated Primarily with Radical Radiotherapy
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Introduction: The aims of this study were to determine patterns of outcome and prognostic factors in human papilloma virus positive oropharyngeal squamous cell carcinoma (OPSCC+) treated primarily with radical radiotherapy. Materials and methods: We identified 54 patients at a tertiary hospital in South Australia who received treatment with curative intent for OPSCC+ with radical radiotherapy ± chemotherapy or cetuximab from 1st January, 2010 to 31st March, 2017. We explored the effect of patient, tumour and radiotherapy factors on treatment outcomes. The primary endpoint was overall survival and the secondary endpoint was disease-free survival. Results: The median age was 59, with most patients being male (82%). The majority had advanced disease (89% stage IV). The median follow-up was 22.5 months. The one-year and two-year overall survival and disease-free survival rates were 89% and 79% and 77% and 68% respectively. Active smoking during radiotherapy was associated with trends to shortened overall survival (p=0.084) and reduced time to recurrence (p˃0.1). However, there was no statistically significant relationship between any other patient, tumour or treatment factors and disease-free or overall survival. Discussion: Despite advanced stage at presentation, radiotherapy ± concurrent systemic therapy results in favorable outcomes for OPSCC+. Active smoking during radiotherapy may compromise overall survival. We strongly recommend smoking cessation prior to commencing radiotherapy for OPSCC+. In addition, we note that smokers involved in de-intensification trials may be at increased risk of poor outcomes.
Keywords
Subjects
Oncology & CancerAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Clinical & Experimental Oncology.
Research article · 10 Apr 2025
Multitargets and Interactions of Wortmannin with MSC-Mitogenic Proteins Validate the Enhanced Antiproliferative Effect of MSCSecretome on Breast Cancer Michigan Cancer Foundation-7 Cells
Mini review · 24 Jan 2025
Fractal Analysis in Medical Images
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Clinical & Experimental Oncology
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Ha Lu”
- BylineArticles whose byline prints “Anni Chen”
- BylineArticles whose byline prints “Ivan Iankov”
- BylineArticles whose byline prints “Myo Min”
- BylineArticles whose byline prints “Raghu Gowda”
- BylineArticles whose byline prints “Rahul Mukherjee”
- BylineArticles whose byline prints “Daniel Roos”
- BylineArticles whose byline prints “Hien Le”
